Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Glioma 1

Interventions

AZD 6244 11trametinib 4pirfenidone 3mirdametinib 2dabrafenib 2cabozantinib 2Imatinib Mesylate 2tipifarnib 1peginterferon alfa-2b 1nilotinib 1cediranib 1binimetinib 1Vinblastine 1Surveys and Questionnaires 1Sorafenib 1Pharmacokinetics 1Methotrexate 1Liquid Biopsy 1Gadolinium DTPA 1Fluorodeoxyglucose F18 1Everolimus 1Cryotherapy 1Control Groups 1Acceptance and Commitment Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibroma, Plexiform × nilotinib × CNS × Clear all
NCT01275586 2017-04-12

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Indiana University

Phase EARLY_PHASE1 Completed
6 enrolled 7 charts
CNS

Neurofibroma, Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡